Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.

Abstract	Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and with pritelivir's granted breakthrough therapy designation for the treatment of acyclovir-resistant HSV infections in immunocompromised patients, the target has sparked interest for me-too approaches. We describe the opportunities and limitations of the helicase-primase inhibitor patent portfolio from Phaeno Therapeutics and propose the structure of their drug candidate HN0037, which has been in-licensed from Medshine Discovery.
Authors	Christian Gege, Gerald Kleymann
Journal	Expert opinion on therapeutic patents (Expert Opin Ther Pat) Vol. 32 Issue 9 Pg. 933-937 (Sep 2022) ISSN: 1744-7674 [Electronic] England
PMID	35965439 (Publication Type: Journal Article)
Chemical References	Antiviral Agents Viral Proteins DNA Primase DNA Helicases
Topics	Antiviral Agents (therapeutic use) DNA Helicases DNA Primase Herpes Simplex (drug therapy) Humans Patents as Topic Viral Proteins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!